Two public biotechs seek to merge, focusing on desmoid tumors. But Nasdaq is not guaranteed

Two biotechs are looking to merge early next year, and as negotiations are ongoing, investors still need to sign off on the deal.

Oncology-focused Advaxis is in the early stages of merging with Ayala, a biotech incorporated in Delaware and has its primary operations located in Israel.